HomeProductsMaterials ScienceMOF LigandsNitrogen containing MOF ligandsOmilancor
Chemical structure of CAS 1912399-75-7

Omilancor

CAS No.1912399-75-7
MDL No.N/A
MFC30H24N8O2
MW528.60
InChI KeyMVHWZNBAQIGPOQ-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

Omilancor (BT-11) is an orally active LANCL2-binding compound for treating inflammatory bowel disease with a Kd value of 7.7 µM.

CAS No.1912399-75-7
Product NameOmilancor
Heavy Atom Count40Rotatable Bond Count4
Atom Stereo Count0Bond Stereo Count0
HBA6HBD2
TPSA123.760 ŲCharge0
Exact Mass528.20222Complexity1680.00
pKa5.875XLogP4.161

Related Articles

Studies related to this compound and its mechanism of action

Oral Omilancor Treatment Ameliorates Clostridioides difficile Infection During IBD Through Novel Immunoregulatory Mechanisms Mediated by LANCL2 Activation.

Inflammatory bowel diseases • Vol. 30, Issue 1 • 2024
PMID: 37436905DOI: 10.1093/ibd/izad124

Treating Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory Mechanism for Patients With Ulcerative Colitis and Crohn's Disease.

Inflammatory bowel diseases • Vol. 30, Issue 4 • 2024
PMID: 37934790DOI: 10.1093/ibd/izad258

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Immunology • Vol. 160, Issue 1 • 2020
PMID: 32020584PMC: PMC7160657DOI: 10.1111/imm.13175

The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial.

Inflammatory bowel diseases • Vol. 26, Issue 4 • 2020
PMID: 31077582DOI: 10.1093/ibd/izz094

Documentation